Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSAVACassava Sciences$1.61-0.6%$1.93$1.15▼$42.20$77.78M-1.482.97 million shs431,573 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSAVACassava Sciences-0.62%+2.55%+15.83%-32.35%-92.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSAVACassava Sciences3.6059 of 5 stars3.32.00.04.71.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSAVACassava Sciences 2.50Moderate Buy$54.503,285.09% UpsideCurrent Analyst Ratings BreakdownLatest SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSAVACassava Sciences-$97.22M-$1.45N/AN/AN/AN/A-88.05%-64.98%5/9/2025 (Estimated)Latest SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSAVACassava SciencesN/A3.553.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipSAVACassava Sciences9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSAVACassava Sciences3048.31 million43.78 millionOptionableSAVA HeadlinesRecent News About These CompaniesCassava Consciousness from The Tamarind Galaxy part twoMay 1 at 2:19 PM | modernghana.comCassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCMay 1 at 7:30 AM | globenewswire.comTargeted and random mutagenesis of cassava brown streak disease susceptibility factors reveal molecular determinants of disease severityApril 30 at 4:14 PM | elifesciences.orgCassava Sciences appoints new SVP of Clinical DevelopmentApril 23, 2025 | investing.comCassava Sciences chief medical officer James Kupiec to retireApril 22, 2025 | markets.businessinsider.comCassava's Chief Medical Officer to retireApril 21, 2025 | msn.comCassava Sciences Chief Medical Officer Kupiec RetiresApril 21, 2025 | marketwatch.comCassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical DevelopmentApril 21, 2025 | globenewswire.comWhy Cassava Sciences, Inc.’s (SAVA) Stock Is Up 5.51%April 15, 2025 | aaii.comFarmers Need Science Solutions in Their Hands Sooner Than LaterApril 9, 2025 | ipsnews.netShort Interest in Cassava Sciences, Inc. (NASDAQ:SAVA) Declines By 17.8%April 3, 2025 | marketbeat.comDown -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a TurnaroundApril 1, 2025 | zacks.comIs the Future Bleak for SAVA Stock Following Another Setback?March 31, 2025 | zacks.comNotable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focusMarch 30, 2025 | msn.comCassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugMarch 26, 2025 | reuters.comEnd of the line for Cassava's troubled Alzheimer's programmeMarch 26, 2025 | pharmaphorum.comCassava ends simufilam Alzheimer’s programme after second Phase III failureMarch 26, 2025 | finance.yahoo.comSAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyMarch 26, 2025 | zacks.comCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 26, 2025 | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 26, 2025 | markets.businessinsider.comCassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA Company DescriptionsCassava Sciences NASDAQ:SAVA$1.61 -0.01 (-0.62%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 05/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
